GLP-1 Agonists Resource Center: Clinical Evidence, Safety, and Emerging Therapies

April 20, 2026

Table of Contents

Introduction

GLP-1 receptor agonists have become one of the most significant medication classes in modern metabolic medicine. Originally developed for the treatment of type 2 diabetes, these therapies have expanded into broader use for weight management, cardiometabolic risk reduction, and comprehensive metabolic care.

In recent years, awareness of GLP-1 medications has increased significantly as new therapies have demonstrated meaningful clinical benefits across multiple patient populations. Medications such as semaglutide, liraglutide, and dulaglutide have been studied extensively and are now commonly used in clinical practice. More recently, dual incretin therapies such as tirzepatide have emerged that combine multiple metabolic pathways to enhance treatment outcomes.

For healthcare professionals, the rapid expansion of GLP-1 research and treatment options makes it increasingly important to stay informed about best practices, dosing considerations, safety concerns, and evolving clinical guidelines.

This resource center brings together educational articles, continuing education programs, research summaries, and expert insights related to GLP-1 therapies. It is designed to help clinicians deepen their understanding of incretin-based medications and apply the latest evidence to real-world patient care.

What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists are medications that mimic the hormone glucagon-like peptide-1 (GLP-1), an incretin hormone naturally produced in the gut. This hormone plays a central role in regulating blood glucose levels, appetite, and digestive processes.

In healthy individuals, GLP-1 is released after food intake and signals the pancreas to increase insulin secretion when blood glucose levels rise. It also suppresses glucagon release, slows gastric emptying, and contributes to feelings of satiety.

GLP-1 receptor agonist medications replicate these physiological effects. By activating GLP-1 receptors throughout the body, these medications help regulate glucose metabolism and support improved glycemic control.

Key mechanisms of GLP-1 medications include:

stimulation of insulin secretion when blood glucose levels are elevated
reduction of glucagon production
delayed gastric emptying
appetite suppression and reduced caloric intake

Together, these effects contribute to improved metabolic control, weight reduction, and better cardiometabolic outcomes.

For a deeper overview of incretin therapies and how they compare across medication classes:

GLP-1 and GIP/GLP-1 Receptor Agonist Interactive Comparison Chart

Common GLP-1 Medications

Several GLP-1 receptor agonists are widely used in clinical practice. While these medications share a similar mechanism of action, they differ in pharmacokinetics, dosing schedules, and therapeutic indications.

Common medications include:

semaglutide
tirzepatide
dulaglutide
liraglutide

Some therapies are administered daily, while others are given once weekly depending on the formulation.

Newer treatments have expanded the incretin therapy landscape. For example, tirzepatide activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. By targeting multiple metabolic pathways, these dual incretin therapies may produce stronger metabolic improvements than traditional GLP-1 medications alone.

For additional insight into upcoming treatments and future medication development:

GLP-1 Agonists: Pipeline and Emerging Therapies

Clinical Uses for GLP-1 Therapies

GLP-1 receptor agonists are used across several areas of metabolic medicine.

Type 2 Diabetes Management

GLP-1 therapies improve glycemic control and can significantly reduce hemoglobin A1c levels. They are often prescribed when lifestyle interventions and first-line therapies alone are insufficient.

For the latest clinical guidance on diabetes medication strategies:

Stepwise Treatment of Type 2 Diabetes

Weight Management

GLP-1 medications influence appetite regulation and satiety, which makes them valuable tools in obesity treatment. Clinical trials have demonstrated meaningful weight reduction in many patients using GLP-1 therapies, particularly when combined with lifestyle changes.

For a detailed overview of GLP-1 therapy and weight-loss outcomes:

Comparison of GLP-1 and GIP/GLP-1 Receptor Agonists

Cardiometabolic Risk Reduction

GLP-1 therapies may also reduce cardiovascular risk in certain patient populations. Some medications in this class have demonstrated cardiovascular benefits in patients with diabetes and elevated risk factors.

For a broader discussion of cardiometabolic medication benefits:

Diabetes Medications: Cardiovascular and Kidney Impact

Safety and Side Effects

Most patients tolerate GLP-1 receptor agonists well, but clinicians should monitor for potential adverse effects.

The most common side effects are gastrointestinal in nature and may include nausea, vomiting, diarrhea, constipation, reduced appetite, and delayed gastric emptying.

Gradual dose titration can help reduce symptom severity and improve medication tolerability.

For a review of more recent side effect concerns and evolving evidence:

Address New GLP-1 Agonist Side Effect Concerns

Vision and Ocular Safety

Some emerging research has explored potential links between GLP-1 therapies and ocular complications.

Keep Potential Eye Risks With GLP-1 Agonists in Sight

Dosing and Prescribing Considerations

Interest in alternative dosing strategies continues to grow in an attempt to manage side effects or reduce medication costs. But the evidence to support these practices is sparse.

Watch for Creative GLP-1 Agonist Dosing

Nutrition and Lifestyle Considerations

Medication therapy is often most effective when combined with supportive nutrition and lifestyle strategies.

Healthcare providers frequently counsel patients on dietary patterns, meal timing, and lifestyle adjustments when initiating GLP-1 therapy.

For practical patient counseling guidance:

Share Nutrition Tips With Patients on a GLP-1 Agonist

Related Clinical Considerations

Medication management strategies may differ in older adults.

Simplify Diabetes Meds in Older Adults

Breastfeeding patients may ask if using a GLP-1 medication is safe for their baby.

Be Ready for Questions About GLP-1 Use in Breastfeeding

Continuing Education

Healthcare professionals can deepen their understanding of GLP-1 therapies through continuing education programs covering topics such as patient selection, dosing strategies, safety monitoring, and integration of lifestyle interventions with medication therapy.

Courses may include:

Conclusion

GLP-1 receptor agonists have reshaped metabolic disease treatment by targeting multiple physiological pathways related to glucose regulation and appetite control.

As research continues to evolve, clinicians benefit from staying informed about emerging therapies, safety considerations, and evolving treatment strategies. This resource center supports healthcare professionals in navigating the expanding body of knowledge surrounding GLP-1 therapies.

FAQ

What are GLP-1 receptor agonists used for?

These medications treat type 2 diabetes, obesity, and cardiometabolic risk.

How much weight can patients lose with GLP-1 therapy?

Outcomes vary among meds, but in clinical studies, patients without diabetes lost up to 20% of their weight with tirzepatide and up to 14% with injectable semaglutide.

Are GLP-1 medications safe long-term?

Evidence supports long‑term use with appropriate clinical monitoring.

Are there more GLP-1 medications in the drug pipeline?

Yes, there are many of these meds in the pipeline that will tentatively be reviewed by the FDA in the next few years.

For additional diabetes treatment insights:

Clinical Capsules: Diabetes Treatment Debate: Should Metformin Still Be Used First?